

FACT SHEET

for Potential Participants in the CLARION-CKD Study

Stock photo. Posed by model.

Thank you for considering the CLARION-CKD Study, which is testing an investigational study drug called KBP-5074 to see if it can make a difference for people with uncontrolled hypertension and chronic kidney disease (CKD).

Why should I join a clinical research study?

- **Access to potential future therapies** – you may receive an investigational study drug that would otherwise be unavailable. There will be no charge for any study-related treatment.
- **Advance understanding** – you would be contributing to medical research that may help other people with uncontrolled hypertension and CKD in the future.
- **Medical care** – you would be provided with extensive information about your health through regular examinations and tests, which may help to uncover undiagnosed medical conditions.

About the CLARION-CKD Study

What is the CLARION-CKD Study?

The aim of the CLARION-CKD Study is to assess the safety and effectiveness of an investigational study drug used with existing blood pressure drugs in people with uncontrolled hypertension and CKD. The investigational study drug will be compared with a placebo, which looks exactly like the investigational study drug but contains no active medication.

Who can take part in the CLARION-CKD Study?

Approximately 600 men and women at around 140 study centers globally are expected to take part. You may be able to participate if you:

- Are 18 years of age or older
- Have uncontrolled hypertension
- Are taking 2 or more blood pressure drugs
- Have moderate (Stage 3b) or severe (Stage 4) CKD.

There are other criteria that you will need to meet to qualify, which the study team will discuss with you.

How long will the CLARION-CKD Study last?

The study is expected to last up to 62 weeks, during which you will be asked to attend the study center a number of times to undergo medical tests and assessments. A more detailed breakdown follows.


- You will be assessed to see if you can join the study

Follow-up

- You will stop taking your study drug
- The study team will assess your health closely for 4 weeks

Randomized, double-blind withdrawal period

- You will be randomly assigned again to receive either KBP-5074 or placebo for 4 weeks



Open-label placebo run-in

- Everyone will receive the placebo for 2 weeks
- This is to ensure you are stable on your usual blood pressure drugs before study treatment starts

Double-blind treatment

- You will receive either KBP-5074 or placebo for 24 weeks
- This will be randomly assigned, like flipping a coin

Open-label treatment

- You may now receive KBP-5074 for 24 weeks if you had been receiving the placebo and you are eligible

What happens during visits to the study center?

At each visit, you will undergo tests and assessments to check your health and determine how your body is responding to the study drug. The following assessments will occur during the study:

- Questions about you, your health, medical history, and current and previous medications you have been or are taking
- Physical examination, including measurements of your height, weight, and waist circumference
- Vital signs – measurements of your blood pressure, heart and breathing rate, and temperature
- ECG
- Blood samples collected
- Urine samples collected
- You will be given enough of the study drug to take at home.

If you would like to learn more about the CLARION-CKD Study, please contact:

Study center: SCKE Health

Contact person: Diem or Allan

Address: 23141 Moulton Parkway Ste 102
Laguna Hills, CA 92653

Telephone: 949-916-9100

Email: sckeresearch@gmail.com

Participation is entirely voluntary, and you can withdraw from the study at any time. Contacting us does not mean that you must join the study or that you will be able to participate.

